Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

340P - Molecular profiling in pancreatic cancers: Therapeutic and prognostic impact

Date

27 Jun 2024

Session

Poster Display session

Presenters

Anthony Tarabay

Citation

Annals of Oncology (2024) 35 (suppl_1): S119-S161. 10.1016/annonc/annonc1481

Authors

A. Tarabay1, A. Boileve2, C. Smolenski3, L. Antoun1, M. Valery3, T. Pudlarz1, D. Malka2, V. Boige4, A. Hollebecque3, M.P. Ducreux1

Author affiliations

  • 1 Gustave Roussy - Cancer Campus, Villejuif/FR
  • 2 Institut Gustave Roussy, Villejuif/FR
  • 3 Institut Gustave Roussy, Villejuif, Cedex/FR
  • 4 Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 340P

Background

Pancreatic ductal adenocarcinoma (PDAC) represents the third leading vause of cancer-related deaths worldwide. Mostly diagnosed at locally advanced or metastatic stage, therapeutic strategies are limited, especially from the second line onwards. Precision medicine currently offers new potentially effective therapeutic options, based on actionable molecular alterations (AMA) according to the ESMO Scale of Clinical Actionability for Molecular Targets (ESCAT). However, access to molecular profiling in pancreatic cancer remains limited and clinical benefits are controversial.

Methods

We conducted a retrospective study on all patients over 18 years of age diagnosed with pancreatic adenocarcinoma and who underwent molecular profiling since 2010 in our institution as part of personalized medicine clinical trials. Molecular analysis was performed on tumor DNA directly from tumor biopsy or peripheral blood samples.

Results

Out of 342 patients who underwent molecular profiling, 69 patients (20%) had an AMA according to the ESCAT classification (I to III), mostly affecting BRCA1 or BRCA2 genes. Four patients had microsatellite instability (MSI). Only 31 out of 69 patients (45%) were able to receive targeted therapy (TT) based on their AMA. Overall survival (OS) of patients who received targeted treatment (group A) was statistically superior to those with AMA who did not receive targeted therapy (group B), and to those without AMA on molecular profiling (group C), with a median OS of 34.89 months for group A compared to 27.07 months for group B and 21.45 months for group C (p=0.03, adjusted for age at diagnosis, disease stage, KRAS status, and number of chemotherapy lines received at the time of molecular analysis). The same trend was observed for overall survival in metastatic stage with a median OS of 32.88 months for group A compared to 17.58 months for group B and 12.94 months for group C (p=0.0004, adjusted for the number of chemotherapy lines received at the time of molecular analysis).

Conclusions

Twenty percent of pancreatic cancers present an AMA that can be treated with TT, and the AMA-TT combination significantly improves overall survival in patients with pancreatic cancer, regardless of the presence of the molecular anomaly.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.